Q4 2023 Holdings
Filed 2024-02-14 | 48 holdings | $2.1B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $513.0M | 8,494,151 | 24.5% |
| Ambrx Biopharma Inc | COM | 641871108 | $159.9M | 11,231,000 | 7.6% |
| Eyepoint Pharmaceuticals Inc(EYPT) | COM NEW | 30233G209 | $139.5M | 6,038,235 | 6.7% |
| Bridgebio Pharma Inc(BBIO) | COM | 10806X102 | $135.0M | 3,344,179 | 6.4% |
| Arcellx Inc(ACLX) | COMMON STOCK | 03940C100 | $94.4M | 1,700,000 | 4.5% |
| Rayzebio Inc | COM | 75525N107 | $75.4M | 1,213,478 | 3.6% |
| Biomea Fusion Inc(BMEA) | COM | 09077A106 | $51.8M | 3,570,872 | 2.5% |
| Immunovant Inc(IMVT) | COM | 45258J102 | $49.1M | 1,165,000 | 2.3% |
| Alpine Immune Sciences Inc(NVLSEUR) | COM | 02083G100 | $48.6M | 2,550,000 | 2.3% |
| Pharvaris N V(PHVS) | COM | N69605108 | $48.0M | 1,711,460 | 2.3% |
| ALX Oncology Hldgs Inc(ALXO) | COM | 00166B105 | $46.8M | 3,142,079 | 2.2% |
| Tarsus Pharmaceuticals Inc(TARS) | COM | 87650L103 | $45.0M | 2,221,422 | 2.1% |
| Cymabay Therapeutics Inc(CBAYUSD) | COM | 23257D103 | $42.5M | 1,800,000 | 2.0% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $41.8M | 665,000 | 2.0% |
| Crinetics Pharmaceuticals in(CRNX) | COM | 22663K107 | $40.9M | 1,150,000 | 2.0% |
| Apellis Pharmaceuticals Inc(APLS) | COM | 03753U106 | $37.4M | 625,000 | 1.8% |
| Marinus Pharmaceuticals Inc(MRNS*) | COM NEW | 56854Q200 | $35.3M | 3,250,000 | 1.7% |
| Autolus Therapeutics PLC(AUTL) | SPON ADS | 05280R100 | $35.1M | 5,450,000 | 1.7% |
| Olema Pharmaceuticals Inc(OLMA) | COM | 68062P106 | $34.5M | 2,456,800 | 1.6% |
| Immuneering Corp(IMRX) | CLASS A COM | 45254E107 | $30.9M | 4,204,364 | 1.5% |
| Edgewise Therapeutics Inc(EWTX) | COM | 28036F105 | $27.9M | 2,551,989 | 1.3% |
| Aerovate Therapeutics Inc | COM | 008064107 | $27.4M | 1,211,696 | 1.3% |
| Cargo Therapeutics Inc(CRGX) | COM | 14179K101 | $27.4M | 1,182,563 | 1.3% |
| Syndax Pharmaceuticals Inc(SNDX) | COM | 87164F105 | $25.4M | 1,175,000 | 1.2% |
| Korro BIO Inc(KRRO) | COM | 500946108 | $25.4M | 529,170 | 1.2% |
| Rhythm Pharmaceuticals Inc(RYTM) | COM | 76243J105 | $25.3M | 550,000 | 1.2% |
| Abivax SA(ABVX) | SPONSORED ADS | 00370M103 | $22.8M | 2,130,000 | 1.1% |
| Harpoon Therapeutics Inc | COM NEW | 41358P205 | $22.6M | 2,349,060 | 1.1% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $20.2M | 937,080 | 1.0% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $17.8M | 575,000 | 0.9% |
| Ideaya Biosciences Inc(IDYA) | COM | 45166A102 | $16.0M | 450,000 | 0.8% |
| Axonics Inc(AXNX*) | COM | 05465P101 | $15.6M | 250,000 | 0.7% |
| Neurogene Inc(NGNE) | COM | 64135M105 | $14.5M | 746,180 | 0.7% |
| Longboard Pharmaceuticals in | COM | 54300N103 | $14.2M | 2,353,141 | 0.7% |
| Praxis Precision Medicines I(PRAX) | COM NEW | 74006W207 | $14.1M | 633,345 | 0.7% |
| Rocket Pharmaceuticals Inc(RCKT) | COM | 77313F106 | $13.5M | 450,000 | 0.6% |
| Rapt Therapeutics Inc(RAPTEUR) | COM | 75382E109 | $12.3M | 496,750 | 0.6% |
| Disc Medicine Inc(IRON) | COM | 254604101 | $7.2M | 125,000 | 0.3% |
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $5.7M | 1,087,807 | 0.3% |
| Editas Medicine Inc(EDIT)Put | COM | 28106W103 | $5.1M | 500,000 | 0.2% |
| Verve Therapeutics Inc | COM | 92539P101 | $4.9M | 350,000 | 0.2% |
| Lantheus Hldgs Inc(LNTH) | COM | 516544103 | $4.7M | 75,000 | 0.2% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADS | 152309100 | $4.5M | 561,600 | 0.2% |
| Biohaven LTD(BHVN) | COM | G1110E107 | $3.5M | 81,963 | 0.2% |
| GH Research PLC(GHRS) | ORDINARY SHARES | G3855L106 | $3.4M | 593,043 | 0.2% |
| Vyne Therapeutics Inc(VYNE) | COM | 92941V308 | $3.2M | 1,394,336 | 0.2% |
| Bioatla Inc(BCAB) | COM | 09077B104 | $2.9M | 1,181,115 | 0.1% |
| Neumora Therapeutics Inc.(NMRA) | COM | 640979100 | $1.6M | 92,293 | 0.1% |